Metabolic Aspects of Citrate Anticoagulation in Renal Replacement Therapy (Citrate)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01361581
Recruitment Status : Unknown
Verified May 2011 by Charles University, Czech Republic.
Recruitment status was:  Recruiting
First Posted : May 27, 2011
Last Update Posted : May 27, 2011
Ministry of Health, Czech Republic
Information provided by:
Charles University, Czech Republic

Brief Summary:
Citrate anticoagulation is associated with metabolic side effects which are linked to a portion of citrate reaching systemic circulation. Data on significance of systemic gain of citrate and its relationship to method configuration are missing. Patient might also receive certain dose of lactate as a buffer and a dose of glucose if acid-citrate-dextrose solution is used. The authors test variable methods of indirect estimate of systemic dose of citrate which would allow to quantify the metabolic input without mostly unavailable measurements of citrate levels.

Condition or disease
Acute Renal Failure Critical Illness

Study Type : Observational
Estimated Enrollment : 120 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Metabolic Aspects of Citrate Anticoagulation in Renal Replacement Therapy
Study Start Date : January 2008

Resource links provided by the National Library of Medicine

U.S. FDA Resources

ACD (acid-citrate-dextrose)
4% trisodium citrate
unfractionated heparin (UFH)

Biospecimen Retention:   Samples Without DNA
frozen plasma

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   16 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
critically ill intensive care patients

Inclusion Criteria:

  • Acute renal failure on continuous renal replacement therapy for more than 24 hours (CVVH or CVVHDF).

Exclusion Criteria:

  • Absence of consent.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01361581

Czech Republic
Dept of Anaesthesia and Intensive Care, General University Hospital, 1st Medical Faculty, Charles University Recruiting
Prague 2, Czech Republic, 120 00
Contact: Martin Balik, A/Prof   
Principal Investigator: Martin Balik, MD, PhD         
Sponsors and Collaborators
Charles University, Czech Republic
Ministry of Health, Czech Republic

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Martin Balik, A/Prof., MD, PhD, EDIC, 1st Medical Faculty, Charles University, Prague Identifier: NCT01361581     History of Changes
Other Study ID Numbers: NS/10014-4
First Posted: May 27, 2011    Key Record Dates
Last Update Posted: May 27, 2011
Last Verified: May 2011

Keywords provided by Charles University, Czech Republic:
Acute renal failure
Renal replacement therapy

Additional relevant MeSH terms:
Renal Insufficiency
Critical Illness
Acute Kidney Injury
Kidney Diseases
Urologic Diseases
Disease Attributes
Pathologic Processes
Citric Acid
Calcium Chelating Agents
Chelating Agents
Sequestering Agents
Molecular Mechanisms of Pharmacological Action